PTC Therapeutics Inc (FRA:BH3)
€ 36.6 5.2 (16.56%) Market Cap: 2.80 Bil Enterprise Value: 2.16 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 70/100

Q2 2024 PTC Therapeutics Inc Earnings Call Transcript

Aug 08, 2024 / 08:30PM GMT
Release Date Price: €28.6 (-2.05%)
Operator

Good day and thank you for standing by. Welcome to the PTC Therapeutics second-quarter 2024 financial results. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Ron Aldridge, Senior Director of Investor Relations.

Ron Aldridge
PTC Therapeutics Inc - Senior Director of Investor Relations

Good afternoon, and thank you for joining us today to discuss PTC Therapeutics' second-quarter 2024 corporate update and financial results. I'm joined today by our Chief Executive Officer, Dr. Matthew Klein; our Chief Business Officer, Eric Pauwels; our Chief Strategy Officer, Kylie O'Keefe; and our Chief Financial Officer, Pierre Gravier.

Today's call will include forward-looking statements based on our current expectations. Please take a moment to review the slide posted on our Investor Relations website in conjunction with the call, which contains information about our forward-looking statements.

Our actual results could materially differ

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot